QT Imaging Holdings Reports Q4 Operating Loss of USD 700 Thousand
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 18 2026
0mins
Should l Buy QTI?
Source: moomoo
- Company Overview: Q4 Operating Income for Q Holdings is reported at USD 700,000.
- Financial Performance: The financial results indicate a stable performance in the fourth quarter.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QTI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QTI
Wall Street analysts forecast QTI stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 7.020
Low
Averages
High
Current: 7.020
Low
Averages
High
About QTI
QT Imaging Holdings, Inc. is a medical device company engaged in the research, development, and commercialization of body imaging systems using low-frequency sound waves. The Company's products include QTI Breast Acoustic CT Scanner and QTviewer Software. QTI’s Breast Acoustic CT scanner with QTViewer viewer software is the only three-dimensional (3D) imaging device to receive United States Food and Drug Administration (FDA) clearance for use as a transmission and reflection ultrasonic imaging system of a patients breast. QTviewer is its proprietary image viewing and analysis platform, purpose-built to interpret the rich, quantitative datasets generated by the QTI Breast Acoustic CT™ scanner. The QTviewer allows users to rotate, zoom, and cross-navigate entire breast volumes. Whether isolating lesions or exploring architectural distortion, radiologists can interact with the data dynamically to gain an understanding of tissue structure and lesion morphology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
QT Imaging Files $100M Mixed Securities Shelf Registration
- Securities Shelf Filing: QT Imaging has filed a $100 million mixed securities shelf registration, which, while not an offer to sell, indicates the company's active engagement in capital markets and may pave the way for future financing opportunities.
- Financial Performance: The company reported a GAAP EPS of -$0.10 and revenue of $8.28 million, and despite the losses, QT Imaging reaffirmed its FY26 outlook, demonstrating confidence in future growth prospects.
- Preliminary Financial Data: Preliminary figures show a GAAP EPS of -$0.10 with revenue slightly increasing to $8.3 million, indicating the company's stability in the market, although it still faces challenges in achieving profitability.
- Quant Rating Insight: Seeking Alpha's Quant Rating on QT Imaging provides context with historical financial data, revealing that despite current underperformance, there remains a divergence in market perceptions regarding the company's future potential.
See More
QT Imaging Holdings Inc. Confirms 2026 Revenue Guidance of $39 Million from Contracted Scanner MOQs and Initial QTI Cloud Platform Earnings
Financial Overview: QTI Holdings has reported a revenue guidance of $39 million for the year 2026.
Revenue Sources: The anticipated revenue is derived from contracted scanner MOQs and the initial QTI cloud platform.
See More
QT Imaging Announces Financial Results for the Fourth Quarter and Full Year 2025
Financial Performance Overview: The Q4 and full-year financial results for 2025 indicate significant growth and profitability for the company, showcasing strong revenue streams and effective cost management.
Key Metrics and Highlights: The report highlights key performance indicators, including increased earnings per share and a robust return on investment, reflecting the company's strategic initiatives and market positioning.
Market Trends and Insights: Analysis of market trends suggests favorable conditions for continued growth, with emerging opportunities in various sectors that the company is poised to capitalize on.
Future Outlook and Guidance: The company provides optimistic guidance for the upcoming year, anticipating further expansion and investment in innovation to sustain its competitive edge in the market.
See More
QT Imaging Secures UAE Clearance for Breast Imaging Technology
- Market Access Milestone: QT Imaging's Breast Acoustic CT™ scanner has received official classification and clearance from the UAE Emirates Drug Establishment, marking the company's formal entry into the UAE medical market and paving the way for future commercialization efforts.
- Revenue Pipeline Established: The exclusive distribution agreement with Al Naghi Medical Co. is projected to generate $24 million in revenue for QT Imaging through 2028, highlighting the technology's potential in the rapidly growing Middle Eastern healthcare market.
- Healthcare Market Demand: According to data from Elobaid et al., breast cancer accounts for 25% of all cancer cases in the UAE, underscoring the urgent need for safe and effective breast imaging solutions, which further enhances QT Imaging's market opportunities.
- Global Strategic Expansion: This clearance not only strengthens QT Imaging's commercial presence in the UAE but also complements its operations in Saudi Arabia, showcasing the company's strategic positioning in two of the largest healthcare markets in the Middle East.
See More
QT Imaging Receives FDA Clearance for Enhanced Breast Imaging Technology
- FDA Approval for New Configuration: QT Imaging's Breast Acoustic CT™ scanner has received FDA 510(k) clearance for an updated configuration that enhances imaging coverage of breast tissue near the chest wall, significantly improving diagnostic capabilities and potentially strengthening the company's market position in breast health management.
- Technological Innovation: The new configuration optimizes the scanner's ability to image posterior breast tissue, an area often challenging to capture with standard methods, thereby enhancing overall diagnostic utility and addressing the market demand for high-precision breast imaging solutions.
- Enhanced Data Processing: The scanner generates both reflection-mode and transmission-mode ultrasound data to reconstruct 3D images and quantify fibroglandular tissue volume (FGV) and the ratio of fibroglandular tissue to total breast volume (TBV), providing valuable insights for breast health assessment that are expected to drive market acceptance of related products.
- Strategic Company Direction: QT Imaging is committed to improving global health outcomes through innovative technologies, and the new FDA clearance will provide robust support for the commercialization and technological development of its breast imaging solutions, further solidifying its leadership position in the medical device industry.
See More
QT Imaging Appoints New Medical Advisor
- Appointment of Medical Advisor: QT Imaging has appointed Dr. Mary W. Yamashita as Medical Advisor, who will provide strategic guidance on clinical interpretation standards and structured reporting frameworks, aiming to enhance clinical integration and user experience of the company's technologies.
- Professional Background: Dr. Yamashita serves as Section Chief of Breast Imaging at USC and has extensive experience in breast cancer screening and diagnosis, having participated in multicenter clinical trials, thereby enhancing the company's expertise in breast health management.
- Driving Technological Innovation: Dr. Yamashita will advance the development of a radiation-free 3D breast imaging solution, focusing on improving screening accuracy and safety, aligning with the company's mission to expand access to safe and comfortable breast imaging.
- Commitment to Clinical Excellence: CEO Raluca Dinu emphasized that Dr. Yamashita's involvement will strengthen the company's scientific foundation and accelerate the adoption of best-in-class structured reporting practices, thereby improving diagnostic accuracy and workflow efficiency.
See More
QT Imaging Files $100M Mixed Securities Shelf Registration
- Securities Shelf Filing: QT Imaging has filed a $100 million mixed securities shelf registration, which, while not an offer to sell, indicates the company's active engagement in capital markets and may pave the way for future financing opportunities.
- Financial Performance: The company reported a GAAP EPS of -$0.10 and revenue of $8.28 million, and despite the losses, QT Imaging reaffirmed its FY26 outlook, demonstrating confidence in future growth prospects.
- Preliminary Financial Data: Preliminary figures show a GAAP EPS of -$0.10 with revenue slightly increasing to $8.3 million, indicating the company's stability in the market, although it still faces challenges in achieving profitability.
- Quant Rating Insight: Seeking Alpha's Quant Rating on QT Imaging provides context with historical financial data, revealing that despite current underperformance, there remains a divergence in market perceptions regarding the company's future potential.
See More
QT Imaging Holdings Inc. Confirms 2026 Revenue Guidance of $39 Million from Contracted Scanner MOQs and Initial QTI Cloud Platform Earnings
Financial Overview: QTI Holdings has reported a revenue guidance of $39 million for the year 2026.
Revenue Sources: The anticipated revenue is derived from contracted scanner MOQs and the initial QTI cloud platform.
See More
QT Imaging Announces Financial Results for the Fourth Quarter and Full Year 2025
Financial Performance Overview: The Q4 and full-year financial results for 2025 indicate significant growth and profitability for the company, showcasing strong revenue streams and effective cost management.
Key Metrics and Highlights: The report highlights key performance indicators, including increased earnings per share and a robust return on investment, reflecting the company's strategic initiatives and market positioning.
Market Trends and Insights: Analysis of market trends suggests favorable conditions for continued growth, with emerging opportunities in various sectors that the company is poised to capitalize on.
Future Outlook and Guidance: The company provides optimistic guidance for the upcoming year, anticipating further expansion and investment in innovation to sustain its competitive edge in the market.
See More
QT Imaging Secures UAE Clearance for Breast Imaging Technology
- Market Access Milestone: QT Imaging's Breast Acoustic CT™ scanner has received official classification and clearance from the UAE Emirates Drug Establishment, marking the company's formal entry into the UAE medical market and paving the way for future commercialization efforts.
- Revenue Pipeline Established: The exclusive distribution agreement with Al Naghi Medical Co. is projected to generate $24 million in revenue for QT Imaging through 2028, highlighting the technology's potential in the rapidly growing Middle Eastern healthcare market.
- Healthcare Market Demand: According to data from Elobaid et al., breast cancer accounts for 25% of all cancer cases in the UAE, underscoring the urgent need for safe and effective breast imaging solutions, which further enhances QT Imaging's market opportunities.
- Global Strategic Expansion: This clearance not only strengthens QT Imaging's commercial presence in the UAE but also complements its operations in Saudi Arabia, showcasing the company's strategic positioning in two of the largest healthcare markets in the Middle East.
See More
QT Imaging Receives FDA Clearance for Enhanced Breast Imaging Technology
- FDA Approval for New Configuration: QT Imaging's Breast Acoustic CT™ scanner has received FDA 510(k) clearance for an updated configuration that enhances imaging coverage of breast tissue near the chest wall, significantly improving diagnostic capabilities and potentially strengthening the company's market position in breast health management.
- Technological Innovation: The new configuration optimizes the scanner's ability to image posterior breast tissue, an area often challenging to capture with standard methods, thereby enhancing overall diagnostic utility and addressing the market demand for high-precision breast imaging solutions.
- Enhanced Data Processing: The scanner generates both reflection-mode and transmission-mode ultrasound data to reconstruct 3D images and quantify fibroglandular tissue volume (FGV) and the ratio of fibroglandular tissue to total breast volume (TBV), providing valuable insights for breast health assessment that are expected to drive market acceptance of related products.
- Strategic Company Direction: QT Imaging is committed to improving global health outcomes through innovative technologies, and the new FDA clearance will provide robust support for the commercialization and technological development of its breast imaging solutions, further solidifying its leadership position in the medical device industry.
See More
QT Imaging Appoints New Medical Advisor
- Appointment of Medical Advisor: QT Imaging has appointed Dr. Mary W. Yamashita as Medical Advisor, who will provide strategic guidance on clinical interpretation standards and structured reporting frameworks, aiming to enhance clinical integration and user experience of the company's technologies.
- Professional Background: Dr. Yamashita serves as Section Chief of Breast Imaging at USC and has extensive experience in breast cancer screening and diagnosis, having participated in multicenter clinical trials, thereby enhancing the company's expertise in breast health management.
- Driving Technological Innovation: Dr. Yamashita will advance the development of a radiation-free 3D breast imaging solution, focusing on improving screening accuracy and safety, aligning with the company's mission to expand access to safe and comfortable breast imaging.
- Commitment to Clinical Excellence: CEO Raluca Dinu emphasized that Dr. Yamashita's involvement will strengthen the company's scientific foundation and accelerate the adoption of best-in-class structured reporting practices, thereby improving diagnostic accuracy and workflow efficiency.
See More
